NCT05912556

Brief Summary

The objective of this study is to assess the effectiveness of two digital programs for providing mental stimulation, improving cognition, and inducing changes in brain structure and function.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
817

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Jul 2023

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 8, 2023

Completed
14 days until next milestone

First Posted

Study publicly available on registry

June 22, 2023

Completed
13 days until next milestone

Study Start

First participant enrolled

July 5, 2023

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 11, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 11, 2025

Completed
Last Updated

July 30, 2026

Status Verified

July 1, 2026

Enrollment Period

1.7 years

First QC Date

June 8, 2023

Last Update Submit

July 29, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Overall Composite from Creyos (formerly Cambridge Brain Sciences)

    The Overall Composite is derived from the 12 tests in the Creyos battery.

    Study Day 0 to Study Day 84

Secondary Outcomes (7)

  • Concentration Domain Score from Creyos

    Study Day 0 to Study Day 84

  • Memory Domain Score from Creyos

    Study Day 0 to Study Day 84

  • Planning Domain Score from Creyos

    Study Day 0 to Study Day 84

  • Reasoning Domain Score from Creyos

    Study Day 0 to Study Day 84

  • Structural Brain Composite from Magnetic Resonance Imaging (MRI)

    Study Day 0 to Study Day 84

  • +2 more secondary outcomes

Study Arms (2)

Cohort A

OTHER

Remote-Only subjects

Device: Digital Program 1Device: Digital Program 2

Cohort B

OTHER

Remote + Imaging subjects

Device: Digital Program 1Device: Digital Program 2

Interventions

2/3 of randomized subjects use digital program 1 for 12 weeks to provide mental stimulation

Cohort ACohort B

1/3 of randomized subjects use digital program 2 for 12 weeks to provide mental stimulation

Cohort ACohort B

Eligibility Criteria

Age25 Years - 80 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Subjects 25-80 years of age.
  • Ability to understand and speak English, follow written and verbal instructions (English), and give informed consent (English), as assessed by study staff.
  • Ability to comply with all the testing and study requirements, including the ability to independently use a video conferencing tool and the ability to independently use a computer to access the web.
  • Ability to independently complete a daily, online intervention and outcome assessments using a web browser compatible with the intervention and assessment software on a reliable, internet-connected laptop or desktop computer.

You may not qualify if:

  • Current, controlled (requiring treatment) or uncontrolled psychiatric diagnosis, including but not limited to posttraumatic stress disorder, psychosis, bipolar illness, pervasive developmental disorder, severe obsessive compulsive disorder, severe depressive or severe anxiety disorder, conduct disorder, attention-deficit/hyperactivity disorder, or other symptomatic manifestations that in the opinion of the Investigator may confound study data/assessments.
  • Current, controlled (requiring treatment) or uncontrolled neurological diagnosis, including but not limited to Alzheimer's Disease, other dementias, mild cognitive impairment, Huntington's Disease, Parkinson's Disease, multiple sclerosis, stroke, epilepsy, aphasia, or other condition that in the opinion of the Investigator may confound study data/assessments.
  • Any other medical condition in the last 90 days that in the opinion of the Investigator may confound study data/assessments.
  • Has been under the care of a caretaker or has not been living independently in the last 90 days.
  • In the last three years has used any of the following for more than two weeks continuously: Online courses, Online brain training programs
  • Known sensitivity (such as headaches, dizziness, nausea) to bright, stimulating video displays.
  • History of seizures (excluding febrile seizures), or significant motor or vocal tics, including but not limited to Tourette's Disorder and photo-sensitive epilepsy.
  • Visual acuity that cannot be corrected that prevents or negatively impacts computer activity.
  • Has participated in a clinical trial within 90 days prior to screening.
  • Pregnancy or planning to become pregnant.
  • Unwillingness or inability to comply with imaging safety protocols.
  • Metal implants or exposure to shrapnel.
  • Left-handed or ambidextrous.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Lumos Labs, Inc.

San Francisco, California, 94108, United States

Location

Study Officials

  • Kevin Madore, PhD

    Lumos Labs, Inc.

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 8, 2023

First Posted

June 22, 2023

Study Start

July 5, 2023

Primary Completion

March 11, 2025

Study Completion

March 11, 2025

Last Updated

July 30, 2026

Record last verified: 2026-07

Data Sharing

IPD Sharing
Will share

Deidentified individual participant data underlying the results reported in a peer-reviewed research article will be made available.

Shared Documents
STUDY PROTOCOL, SAP
Time Frame
Concurrent with the publication of a research article with no anticipated end date.
Access Criteria
Qualified investigators for noncommercial research purposes, upon reasonable request to the corresponding author and approval by Lumos Labs, Inc., with a signed data use agreement.

Locations